Do You Gain Weight Back After Stopping Semaglutide?

Weight regain after stopping semaglutide is a well-documented, biology-driven response, not a personal failing — the underlying hormonal changes that drive appetite return once the medicine clears.
Trial data from the STEP 4 extension study show participants regained approximately two-thirds of lost weight within 12 months of stopping the 2.4 mg weekly injection.
Long-term weight management after stopping typically requires a structured plan covering diet, activity and, in some cases, an alternative or continued medical approach, agreed with a prescriber.
Semaglutide for weight loss (Wegovy) is a prescription-only medicine, a qualified prescriber decides whether to continue, change or stop treatment, based on your health and progress.

Most people do regain a significant proportion of lost weight after stopping semaglutide. Clinical trial data show that, on average, participants who discontinued the medicine regained around two-thirds of the weight they had lost within a year of stopping — even when they continued lifestyle changes. That is not a failure of willpower. Semaglutide works by altering the hormonal signals that govern hunger and fullness; when the medicine leaves your system, those signals return to their pre-treatment pattern. These are prescription-only medicines, and any decision about stopping or continuing is one a prescriber should make with you based on your full clinical picture.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

What the evidence says, and what it means for stopping Wegovy

Why does weight come back when you stop semaglutide?

Semaglutide reduces appetite and slows gastric emptying by activating GLP-1 receptors in the gut and brain. That combination makes eating less feel manageable, often dramatically so. But obesity is a chronic condition with strong biological drivers, and the brain's hunger-regulation circuitry does not permanently reset during treatment. Once semaglutide clears your system (it has a roughly one-week half-life, so it takes several weeks to fully wash out), those circuits revert. Hunger signals intensify again, fullness arrives later, and energy intake tends to rise toward pre-treatment levels.

This is why researchers and clinicians increasingly describe GLP-1 medicines as working in the same way as treatment for other chronic conditions, blood pressure medication, for instance. Stopping the medicine does not mean the underlying condition has resolved. The NHS medicines information for semaglutide notes that it is a long-term treatment for weight management, not a short course.

The question of whether everyone regains weight is explored in more detail at our page on that specific question, but the short answer is: the majority do to some degree, though the rate and amount varies.

How much weight do people typically regain after stopping Wegovy?

The clearest evidence comes from the STEP 4 trial, a study in which participants who had lost weight on semaglutide 2.4 mg were then randomised either to continue or to switch to placebo. Those who switched to placebo regained around 6.9% of their body weight (roughly two-thirds of what they had originally lost) over the following 48 weeks, while the group who stayed on treatment continued to lose weight.

The same pattern appeared after the STEP 1 trial's treatment period ended: the original STEP 1 paper in the New England Journal of Medicine found ~15% average weight loss at 68 weeks; follow-up data showed substantial regain after stopping. Similar findings have been replicated across the GLP-1 literature, including for tirzepatide.

It is worth being honest about the numbers: some regain happens quickly, within the first few months. Others maintain more of their loss for longer, particularly if they have built durable habits around eating and activity during treatment. But the hormonal reset tends to win out over time without ongoing intervention.

For context on long-term cost and planning, our Wegovy cost and pricing page covers what private treatment typically involves financially over different time horizons.

Is there a way to stop semaglutide without regaining all the weight?

There is no guaranteed method, but the evidence points toward several factors that reduce regain. Sustained muscle mass matters: people who incorporated resistance exercise during treatment retain more metabolically active tissue, which helps regulate weight over time. Dietary habits built during treatment (specifically higher protein intake and stable eating patterns) also appear protective. Importantly, the speed of stopping may matter too; some prescribers taper the dose rather than ceasing abruptly, though evidence specifically on tapering strategies is still emerging.

Planning the transition well in advance of stopping is sensible. If you know a break is coming (before a holiday, around a busy period at work, or simply because you want to pause) a prescriber can help you build a plan. That conversation is more useful six weeks before stopping than the week after.

Some people who regain weight after stopping go on to restart treatment. Semaglutide can be used again following a break, subject to clinical assessment. The detail on weight changes when stopping Wegovy covers what typically happens in the first weeks and months. Our page on gaining weight after stopping Wegovy also addresses what to do once regain has already started.

What should you do if you are considering stopping?

Talk to your prescriber before stopping, not after. That is the single most useful step. They can review whether you have reached a point of sufficient benefit, whether a dose reduction rather than cessation makes sense, and what follow-up monitoring is appropriate.

For people on treatment through a regulated online pharmacy (where there is no automatic repeat, and every order involves fresh clinical review) this conversation is built into the process. At nume, a GPhC-registered prescriber personally reviews each case; if your circumstances have changed, that review is the right moment to raise stopping or pausing.

You can also read about whether weight comes back after stopping Wegovy specifically, or explore how Wegovy works as a treatment more broadly. If you are weighing up whether to start or restart, starting a free consultation is the first step, a prescriber will assess your full history, not just your BMI.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions